Rocgel will be distributed in France and in French-speaking African countries, BioProgress said. The product is currently prescription-only but has the potential, and registration approvals, for sales into the over-the-counter healthcare market.
BioProgress said that its high recognition in French-speaking markets also gives the product potential for line extensions through the company’s suite of enabling drug delivery technologies, in particular Solupol.
The company also said that it has out-licensed two low-growth brands in the Dexo portfolio, Dimegan and Mucipulgite. Richard Trevillion, CEO of BioProgress, said: “Rocgel is a highly recognised brand which brings the potential of both line extensions using our drug delivery technologies and of launching the brand in the over-the-counter market.
“The company expects to announce further accretive organic product acquisitions during the course of 2007 as we execute our strategy of marketing high-growth, differentiated and Xgel-enhanced products in both the prescription-only and OTC markets.”